drugset / Trial / NCT04171752

Elafibranor Pharmacokinetic Parameters in Elderly Healthy Volunteers

NCT04171752

Phase 1 Completed 21 enrolled Genfit
Non-randomizedParallel-groupOpen-labelBasic science

Summary

In the elderly, pharmacokinetics is altered. Gastric juice pH is elevated which influences drug solubility and absorption. Drug distribution is decreased in the elderly because of decreased cardiac output, increased peripheral vascular resistance, diminished blood flow in the liver and the kidneys, reduced total amount of water in the body. Drug metabolism and biotransformation mainly take place in the liver and is often reduced. Drug elimination is altered very often because of reduced excretory (renal and hepatic) function. All these changes may lead to significant pharmacokinetic changes in geriatric population. A formal pharmacokinetic clinical study is being conducted in order to assess the need of dose adjustment in the elderly population.

Timeline

Start
2019-11-22
Primary completion
2020-03-22
Completion
2020-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Elafibranor Small molecule 120 mg Oral

Indications

No indication recorded.